Imagen de Portada
Código QR

WHO GOOD PRACTICES FOR RESEARCH AND DEVELOPMENT FACILITIES OF PHARMACEUTICAL PRODUCTS.

Background In view of the need for the development of health products, including the research and development for the treatment of COVID-19 therapies, the World Health Organization (WHO) Prequalification Inspection Services Team (PQT INS) raised the urgency for the development of life cycle appropri...

Descripción completa

Publicado en:WHO Drug Information Vol. 35; no. 3; pp. 637 - 662
Formato: glossary Journal Article
Publicado: World Health Organization 2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=153891538&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 153891538
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10109609
        6FV
      jtl: WHO Drug Information
      issn: 10109609
      maglogo: N
    pubinfo:
      dt: 2021
      vid: 35
      iid: 3
      pid: 437
      pub: World Health Organization
    artinfo:
      ui:
        153891538
        153891538
        153891538
        153891538
      ppf: 637
      ppct: 25
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: WHO GOOD PRACTICES FOR RESEARCH AND DEVELOPMENT FACILITIES OF PHARMACEUTICAL PRODUCTS.
      aug:
      sug:
        subj:
          World Health Organization
          Pharmaceutical Companies Standards
          Drug Design Standards
          Research, Medical Standards
          Product Development Standards
          Quality Management, Organizational
          Risk Management
          Sanitation
          Hygiene
          Contract Services
          Quality Control (Technology)
          Audit
          Staff Development
          Materials Management
          Documentation
      ab: Background In view of the need for the development of health products, including the research and development for the treatment of COVID-19 therapies, the World Health Organization (WHO) Prequalification Inspection Services Team (PQT INS) raised the urgency for the development of life cycle appropriate good practices text to address the manufacturing of developmental batches, pilot batches and the sequential stability data that are submitted in product applications (dossiers) for marketing authorization and the prequalification of medical products.
      pubtype: Academic Journal
      doctype:
        glossary
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N